TriangleNCT01664897 · OUTCOME
Event-free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Weeks
- Interval / dispersion
- Full Range
- Time frame
- Up to 21 weeks
What was measured
Time from date of treatment start until the date of first objective documentation of disease-relapse.
Groups in this outcome
Treatment (Erlotinib Hydrochloride)
Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Erlotinib Hydrochloride: Given PO Laboratory Biomarker Analysis: Correlative studies
| Group | Source count |
|---|---|
| Treatment (Erlotinib Hydrochloride) | 29 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Erlotinib Hydrochloride) | 5 | Not reported | 1.7 | 21.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.7
- upper Limit
- 21.0
- value
- 5
- denoms
- counts
- group Id
- OG000
- value
- 29
- units
- Participants
- description
- Time from date of treatment start until the date of first objective documentation of disease-relapse.
- dispersion Type
- Full Range
- groups
- description
- Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Erlotinib Hydrochloride: Given PO Laboratory Biomarker Analysis: Correlative studies
- id
- OG000
- title
- Treatment (Erlotinib Hydrochloride)
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Up to 21 weeks
- title
- Event-free Survival
- type
- PRIMARY
- unit Of Measure
- Weeks
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice